DexCom, Inc.

NasdaqGS DXCM

DexCom, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD 535.00 M

DexCom, Inc. Free Cash Flow is USD 535.00 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 7.04% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • DexCom, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 499.80 M, a 91.27% change year over year.
  • DexCom, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 261.30 M, a 87.31% change year over year.
  • DexCom, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 139.50 M, a -47.24% change year over year.
  • DexCom, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 264.40 M, a 419.45% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
NasdaqGS: DXCM

DexCom, Inc.

CEO Mr. Kevin Ronald Sayer
IPO Date April 14, 2005
Location United States
Headquarters 6340 Sequence Drive
Employees 9,500
Sector Health Care
Industries
Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

INMD

InMode Ltd.

USD 16.07

0.63%

EW

Edwards Lifesciences Corporation

USD 71.04

-0.07%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

IART

Integra LifeSciences Holdings Corporation

USD 21.93

-1.62%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

PEN

Penumbra, Inc.

USD 252.89

2.41%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

StockViz Staff

January 15, 2025

Any question? Send us an email